UBS/CALL/ROCHE GS/380.004/0.025/19.12.25 Stock

Warrant

CROGQU

CH1147771203

Real-time Bid/Ask 03:33:41 2024-05-28 am EDT
0.033 CHF / 0.042 CHF +18.75% Intraday chart for UBS/CALL/ROCHE GS/380.004/0.025/19.12.25
1 month-20.00%
3 months-5.88%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-27 0.032 +3.23%
24-05-24 0.031 +3.33%

Delayed Quote Swiss Exchange

Last update May 27, 2024 at 11:20 am EDT

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
CROGQU
ISINCH1147771203
Date issued 2021-12-15
Strike 380 CHF
Maturity 2025-12-19 (571 Days)
Parity 40 : 1
Emission price 1.15 CHF
Emission volume N/A
Settlement Por entregas
Currency CHF

Technical Indicators

Highest since issue 1.48 CHF
Lowest since issue 0.03 CHF
Delta0.06x
Omega 8.081
Premium66.07x
Gearing127.72x
Moneyness 0.6050
Difference Strike 148.4 CHF
Difference Strike %+39.04%
Spread 0.03 CHF
Spread %50.00%
Theoretical value 0.0375
Implied Volatility 24.04 %
Total Loss Probability 97.05 %
Intrinsic value 0.000000
Present value 0.0375
Break even 381.50 CHF
Theta-0x
Vega0.01x
Rho0x

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
229.9 CHF
Average target price
279.8 CHF
Spread / Average Target
+21.72%
Consensus
  1. Stock Market
  2. Warrants
  3. CROGQU Warrant